Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. (scientific article published on 28 June 2013)

Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2)

Q33741235

HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate

Q34053101

ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet

Q34657417

Protein kinase CbetaII-mediated phosphorylation of endothelial nitric oxide synthase threonine 495 mediates the endothelial dysfunction induced by FK506 (tacrolimus).

Q35003081

Endothelial protection by high-density lipoproteins: from bench to bedside

Q35217190

Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

Q35572369

Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host

Q35753611

Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures

Q35768215

Endothelial function: a critical determinant in atherosclerosis?

Q35789874

HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3.

Q36056673

The role of high-density lipoprotein in inflammation

Q36228919

Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?

Q36492920

Endothelial and antithrombotic actions of HDL.

Q36500929

HDL cholesterol transport during inflammation

Q36758120

Inflammation impairs reverse cholesterol transport in vivo.

Q37077796

The metabolism and anti-atherogenic properties of HDL.

Q37334590

The contribution of high density lipoprotein apolipoproteins and derivatives to serum paraoxonase-1 activity and function

Q37707214

High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase

Q38299352

The HDL proteome in acute coronary syndromes shifts to an inflammatory profile

Q38501154

Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease

Q42961483

A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression

Q44047905

High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases

Q44269059

Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein

Q44456352

High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life

Q44487862

Functional LCAT is not required for macrophage cholesterol efflux to human serum

Q46315268

The plasma concentration of Lpa-I:A-II particles as a predictor of the inflammatory response in patients with ST-elevation myocardial infarction.

Q46590188

High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection

Q46694269

Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant

Q46925654

The roles of different pathways in the release of cholesterol from macrophages.

Q53531306

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

inflammation

Q101991

P304

page(s)

36-43

P577

publication date

2013-06-28

P1433

published in

Cardiovascular Research

Q4642329

P1476

title

Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome

P478

volume

100

Reverse relations

cites work (P2860)

Q61637469	15-Lipoxygenase-Mediated Modification of HDL3 Impairs eNOS Activation in Human Endothelial Cells
Q51082527	Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency.
Q38612547	Drug and Gene Delivery using Sonoporation for Cardiovascular Disease
Q38773023	Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy
Q38680112	Endothelial dysfunction and vascular disease - a 30th anniversary update
Q40777122	Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.
Q26779667	HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications
Q38220761	High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease
Q37424006	Impact of low high-density lipoprotein-cholesterol level on 2-year clinical outcomes after acute myocardial infarction in patients with diabetes mellitus.
Q49873927	Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients
Q91811617	Mutual Influences between Nitric Oxide and Paraoxonase 1
Q40083837	Plasma cholesterol homeostasis, HDL remodeling and function during the acute phase reaction.
Q98164494	Plasma sphingosine 1-phosphate concentrations and cardiovascular autonomic neuropathy in individuals with type 2 diabetes
Q41087764	Preinduction of heat shock protein 70 protects mice against post-infection irritable bowel syndrome via NF-κB and NOS/NO signaling pathways
Q54913102	Quality Versus Quantity: Making HDL Great Again.
Q47390287	Small dense HDLs display potent vasorelaxing activity, reflecting their elevated content of sphingosine-1-phosphate
Q38760636	The pleiotropic vasoprotective functions of high density lipoproteins (HDL).